During the quarter, net revenue amounted to SEK 65 million, compared to SEK 57 million in the same quarter last year, which corresponds to an increase of 15 percent. For the first half of the year, net revenue landed at SEK 138 million, which is an increase of 30 percent compared to the same period last year. The increase is mainly due to a higher level of activity in our major projects in Greece and Romania, together with increased revenues from ongoing deliveries.
For the full CEO-comment, see the interim report in its entirety.
Christer Wikner, President & CEO, +46 707 647 389, christer.wikner@metacon.com
Mattias Jansson, CFO, +46 722 316 862, mattias.jansson@metacon.com
This information is information that Metacon AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above, at 08:00 CEST on 12 August 2026.
About Metacon
Metacon AB (publ) is a Swedish company that develops, manufactures and supplies systems for hydrogen production. The offering covers the entire chain from design and installation to service and maintenance. The company is listed on the Nasdaq First North Growth Market in Stockholm.
In the field of electrolysis, Metacon develops and supplies complete electrolysis plants for large-scale hydrogen production. Operations are conducted in close collaboration with PERIC Hydrogen Technologies in Handan, China, one of the world's leading players in pressurised alkaline electrolysis technology.
In the field of reforming, the Company develops solutions for hydrogen production based on patented catalytic reactor technology, HIWAR®. These are advanced, highly efficient systems that produce hydrogen through catalytic steam reforming. The systems can be fuelled by biogas, biomethane or other renewable feedstocks such as bioethanol and green ammonia and can be installed without connection to the electricity grid.
For more information, see:
www.metacon.com | LinkedIn: www.linkedin.com/company/metaconab